European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for ...

The global market for primary sclerosing cholangitis (PSC) is on an impressive growth trajectory, with forecasts estimating a ...

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

Single cases of AIH and autoimmune cholangitis (antimitochondrial antibody-negative PBC) overlap have also been reported. Empiric medical treatment of AIH-PBC and AIH-PSC overlap syndromes ...

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

近日，消化领域顶级期刊《胃肠病学》（ Gastroenterology ，IF=25.7）以 封面文章 的形式发表了上海交通大学医学院附属仁济医院 马雄教 授课题组最新研究成果。题为 “Gut Microbiota-Derived Butyrate ...

Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June 2024 (received in August 2024) upon first sale of Ipsen’s Iqirvo® ...

Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been ...

The Gastrointestinal Drugs Advisory Committee (GIDAC) of the US Food and Drug Administration (FDA) met on Friday to discuss ...

Statement from Canada's Chief Veterinary Officer, Dr. Mary Jane Ireland, on the North American African Swine Fever (ASF) Forum "Canada was proud to host the 4th North American African Swine Fever (ASF ...